Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pantoprazole not needed for most patients on anticoagulant/antiplatelet therapies

Publish date:: July 30, 2019

Key clinical point: For most patients taking antiplatelet drugs and/or anticoagulants, pantoprazole is unnecessary.

Major finding: Patients in the pantoprazole group were 48% less likely to bleed from gastroduodenal lesions than those who took placebo (hazard ratio, 0.52; P = .03).

Study details: COMPASS was a placebo-controlled, double-blind, randomized trial involving 17,598 patients with stable peripheral artery disease and cardiovascular disease.

Disclosures: The COMPASS trial was funded by Bayer AG. The investigators disclosed additional relationships with Allergan, Takeda, Janssen, and others.

Citation:

Moayyedi P et al. Gastro. 2019 May 2. doi: 10.1053/j.gastro.2019.04.041.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,